Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; iron oxide red; iron oxide yellow - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 6.25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; iron oxide yellow - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 3.125 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; iron oxide red - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

New Zealand - English - Medsafe (Medicines Safety Authority)

aurobindo pharma nz limited - carvedilol 12.5mg - film coated tablet - 12.5 mg - active: carvedilol 12.5mg excipient: colloidal silicon dioxide crospovidone hypromellose lactose monohydrate macrogol 400 magnesium stearate polysorbate 80 povidone purified water   sucrose titanium dioxide - indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

New Zealand - English - Medsafe (Medicines Safety Authority)

aurobindo pharma nz limited - carvedilol 25mg - film coated tablet - 25 mg - active: carvedilol 25mg excipient: colloidal silicon dioxide crospovidone hypromellose lactose monohydrate macrogol 400 magnesium stearate polysorbate 80 povidone purified water   sucrose titanium dioxide - indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

New Zealand - English - Medsafe (Medicines Safety Authority)

aurobindo pharma nz limited - carvedilol 3.125mg - film coated tablet - 3.125 mg - active: carvedilol 3.125mg excipient: colloidal silicon dioxide crospovidone hypromellose lactose monohydrate macrogol 400 magnesium stearate polysorbate 80 povidone purified water   sucrose titanium dioxide - indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

New Zealand - English - Medsafe (Medicines Safety Authority)

aurobindo pharma nz limited - carvedilol 6.25mg - film coated tablet - 6.25 mg - active: carvedilol 6.25mg excipient: colloidal silicon dioxide crospovidone hypromellose lactose monohydrate macrogol 400 magnesium stearate polysorbate 80 povidone purified water   sucrose titanium dioxide - indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; colloidal anhydrous silica; crospovidone; povidone; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 12.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate; povidone; crospovidone; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 6.25 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; lactose monohydrate; crospovidone; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).